Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;10(5):3199-3205.
doi: 10.3892/ol.2015.3723. Epub 2015 Sep 18.

Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma

Xian-Feng Shen  1 , Xian-Tao Zeng  2 , Zhi-Yuan Jian  1 , Meng Zhou  3 , Ping Zhou  3 , Min Zhang  3
Affiliations

Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma

Xian-Feng Shen et al. Oncol Lett. 2015 Nov.

Abstract

The association between hepatocellular carcinoma (HCC) and the epidermal growth factor (EGF) 61A/G polymorphism has been analyzed in several studies, but results remain inconsistent. Therefore, the aim of the present study was to quantitatively summarize the association between the EGF 61A/G polymorphism and the risk of HCC. The PubMed and EMBASE databases were searched for studies published prior to May 1, 2014. The overall, subgroup and sensitivity analyses were conducted using Comprehensive Meta-Analysis software, version 2.2. In total, 12 published case-control studies, consisting of 2,095 patients with HCC and 3,766 control individuals, were included in the present study. Meta-analysis of the included studies revealed that EGF 61A/G polymorphism contributed to the risk of HCC under all four genetic models, consisting of the G vs. A (OR, 1.25; 95% CI, 1.11-1.40), GG vs. AA (OR, 1.53; 95% CI, 1.26-1.85), GG vs. AG + AA (OR, 1.34; 95% CI, 1.13-1.58) and GG + AG vs. AA (OR, 1.27; 95% CI, 1.08-1.49) comparisons. Subgroup analysis further suggested that EGF 61A/G polymorphism was associated with the risk of HCC in patients and control individuals with liver disease, based on ethnicity and source of control, respectively. No other significance in residual subgroup analysis was observed. The present meta-analysis suggests that the EGF 61A/G polymorphism is associated with an increased risk of HCC and may be a potential marker for liver disease, such as hepatitis B virus infection, hepatitis C virus infection and liver cirrhosis.

Keywords: EGF 61A/G; hepatocellular carcinoma; meta-analysis; polymorphism.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the study selection process.
Figure 2.
Figure 2.
Forest plot describing the association of EGF 61A/G polymorphism with hepatocellular carcinoma based on the G vs. A genetic model.
Figure 3.
Figure 3.
Forest plot of sensitivity analysis, performed by omitting each study in each turn, based on the G vs. A genetic model.
Figure 4.
Figure 4.
Funnel plot for the assessment of publication bias based on the G vs. A genetic model.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Di Costanzo GG. Prospective analysis of risk factors for hepatocellular carcinoma on patients with cirrhosis. Hepatology. 2003;38:1061. doi: 10.1002/hep.1840380438. - DOI - PubMed
    1. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–2899. doi: 10.1200/JCO.2005.03.196. - DOI - PubMed
    1. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 1):S97–S103. doi: 10.1053/j.gastro.2004.09.021. - DOI - PubMed
    1. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 2004;101:1009–1017. doi: 10.1002/cncr.20427. - DOI - PubMed

LinkOut - more resources